Close Menu

News Briefs: Feb 4, 2009

Premium

Cerenis Therapeutics Licenses HDL Therapy IP from Montreal Heart Institute

Cerenis Therapeutics said this week that it has licensed intellectual property from the Montreal Heart Institute Research Centre supporting the development of a drug for aortic valve stenosis based on high-density lipoprotein therapy.

The technology is based on the findings of Jean-Claude Tardif of MHIRC.

Cerenis, which has offices in Toulouse, France, and Ann Arbor, Mich., develops HDL-related compounds for treating cardiovascular and metabolic diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.